Related Experiment Videos
Mutations in the p53 gene in myelodysplastic syndromes
P Jonveaux1, P Fenaux, I Quiquandon
1INSERM U 301, Institut de Génétique Moléculaire, Paris, France.
Abstract:
We have examined p53 alleles in 151 DNAs from patients with myelodysplastic syndrome using single-strand conformation polymorphism analysis of polymerase chain reaction products. We focused our study on the four highly conserved regions of the p53 gene and detected five patients with aberrantly migrating fragments. We confirmed the putative mutation in each case by direct sequencing analysis. Of these five patients, three had chromosome 17 monosomy associated with p53 mutation, one patient showed one mutated p53 allele and one wild-type allele, and the last patient demonstrated only the mutant allele, suggesting a homozygous state. Unlike many other types of human cancers, point mutations in the p53 tumor-suppressor gene appear to be a rare event in myelodysplastic syndromes.
Insights
Point mutations in the p53 tumor-suppressor gene are rare in myelodysplastic syndromes (MDS). This study found mutations in only five of 151 MDS patients, often associated with chromosome 17 abnormalities.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- The p53 tumor-suppressor gene plays a critical role in preventing cancer.
- Mutations in p53 are common in many human cancers.
- The role of p53 mutations in myelodysplastic syndromes (MDS) is less understood.
Purpose of the Study:
- To investigate the frequency and nature of p53 gene mutations in patients with myelodysplastic syndromes (MDS).
- To determine the association between p53 mutations and chromosomal abnormalities in MDS.
Main Methods:
- Single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR) products from 151 MDS patient DNAs.
- Focus on four highly conserved regions of the p53 gene.
- Confirmation of putative mutations by direct sequencing.
Main Results:
- Aberrantly migrating fragments, indicative of mutations, were detected in five patients (3.3%).
- Three of these five patients had chromosome 17 monosomy.
- One patient was heterozygous for a p53 mutation, and one appeared homozygous.
Conclusions:
- Point mutations in the p53 gene are infrequent in myelodysplastic syndromes compared to other cancers.
- p53 mutations in MDS may be associated with chromosome 17 abnormalities.
- Further research is needed to fully elucidate the role of p53 in MDS pathogenesis.